OBJECTIVE: To conduct a replication study to investigate whether the -945 CTGF genetic variant is associated with systemic sclerosis (SSc) susceptibility or specific SSc phenotype. METHODS: The study population comprised 1180 patients with SSc and 1784 healthy controls from seven independent case-control sets of European ancestry (Spanish, French, Dutch, German, British, Swedish and North American). The -945 CTGF genetic variant was genotyped using a Taqman 5' allelic discrimination assay. RESULTS: An independent association study showed in all the case-control cohorts no association of the CTGF -945 polymorphism with SSc susceptibility. These findings were confirmed by a meta-analysis giving a pooled OR = 1.12 (95% CI 0.99 to 1.25), p = 0.06. Investigation of the possible contribution of the -945 CTGF genetic variant to SSc phenotype showed that stratification according to SSc subtypes (limited or diffuse), selective autoantibodies (anti-topoisomerase I or anticentromere) or pulmonary involvement reached no statistically significant skewing. CONCLUSION: The results do not confirm previous findings and suggest that the CTGF -945 promoter polymorphism does not play a major role in SSc susceptibility or clinical phenotype.
OBJECTIVE: To conduct a replication study to investigate whether the -945 CTGF genetic variant is associated with systemic sclerosis (SSc) susceptibility or specific SSc phenotype. METHODS: The study population comprised 1180 patients with SSc and 1784 healthy controls from seven independent case-control sets of European ancestry (Spanish, French, Dutch, German, British, Swedish and North American). The -945 CTGF genetic variant was genotyped using a Taqman 5' allelic discrimination assay. RESULTS: An independent association study showed in all the case-control cohorts no association of the CTGF -945 polymorphism with SSc susceptibility. These findings were confirmed by a meta-analysis giving a pooled OR = 1.12 (95% CI 0.99 to 1.25), p = 0.06. Investigation of the possible contribution of the -945 CTGF genetic variant to SSc phenotype showed that stratification according to SSc subtypes (limited or diffuse), selective autoantibodies (anti-topoisomerase I or anticentromere) or pulmonary involvement reached no statistically significant skewing. CONCLUSION: The results do not confirm previous findings and suggest that the CTGF -945 promoter polymorphism does not play a major role in SSc susceptibility or clinical phenotype.
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: Carmen Fonseca; Gisela E Lindahl; Markella Ponticos; Piersante Sestini; Elisabetta A Renzoni; Alan M Holmes; Paolo Spagnolo; Panagiotis Pantelidis; Patricia Leoni; Neil McHugh; Carmel J Stock; Xu Shi-Wen; Christopher P Denton; Carol M Black; Kenneth I Welsh; Roland M du Bois; David J Abraham Journal: N Engl J Med Date: 2007-09-20 Impact factor: 91.245
Authors: Jonathan P Van Beek; Laura Kennedy; Jason S Rockel; Suzanne M Bernier; Andrew Leask Journal: Arthritis Res Ther Date: 2006-01-16 Impact factor: 5.156
Authors: Dymph Klay; Joanne J van der Vis; Suzan M Roothaan; Tri Q Nguyen; Jan C Grutters; Roel Goldschmeding; Coline H M van Moorsel Journal: Lung Date: 2021-11-23 Impact factor: 2.584
Authors: Xiaodong Zhou; Jong Eun Lee; Frank C Arnett; Momiao Xiong; Min Young Park; Yeon Kyeong Yoo; Eun Soon Shin; John D Reveille; Maureen D Mayes; Jin Hyun Kim; Ran Song; Ji Yong Choi; Ji Ah Park; Yun Jong Lee; Eun Young Lee; Yeong Wook Song; Eun Bong Lee Journal: Arthritis Rheum Date: 2009-12